HC Wainwright Comments on Sutro Biopharma Q2 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Sutro Biopharma in a report released on Monday, November 18th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.87) for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q4 2025 earnings at ($0.96) EPS.

Several other research analysts also recently issued reports on STRO. Truist Financial lowered their price target on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 16th. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a report on Monday, September 16th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $11.00 target price on shares of Sutro Biopharma in a research report on Friday, October 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $12.14.

Sutro Biopharma Price Performance

Shares of NASDAQ:STRO opened at $2.70 on Tuesday. Sutro Biopharma has a one year low of $2.13 and a one year high of $6.13. The company has a market cap of $222.64 million, a price-to-earnings ratio of -1.68 and a beta of 1.17. The firm has a 50 day simple moving average of $3.68 and a 200 day simple moving average of $3.82.

Institutional Trading of Sutro Biopharma

Institutional investors have recently modified their holdings of the business. Gladius Capital Management LP acquired a new position in Sutro Biopharma during the 3rd quarter worth about $28,000. ProShare Advisors LLC lifted its stake in shares of Sutro Biopharma by 49.1% in the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after acquiring an additional 5,373 shares during the period. Intech Investment Management LLC acquired a new position in shares of Sutro Biopharma in the third quarter worth approximately $91,000. Lazard Asset Management LLC bought a new stake in Sutro Biopharma in the first quarter valued at approximately $92,000. Finally, The Manufacturers Life Insurance Company increased its position in Sutro Biopharma by 27.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock valued at $97,000 after purchasing an additional 7,082 shares during the period. Institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.